These shares are getting investors excited today. But why? The post 2 ASX healthcare stocks making huge moves on big news ...

Osteoarthritis drug developer Paradigm says its purchase of an oral drug candidate won't distract it from its key phase III knee trial.

In the IIA group, panelists talked about new in-demand human skill sets, including these (I’m going to try to paraphrase): Cracking the code – looking at the often enigmatic outputs of AI projects, ...